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Abstract
As the limits of existing treatments for cancer are recognized, clearly novel therapies must be considered for successful
treatment; cancer therapy using adenovirus vectors is a promising strategy. However tracking the biodistribution of
adenovirus vectors in vivo is limited to invasive procedures such as biopsies, which are error prone, non-quantitative, and do
not give a full representation of the pharmacokinetics involved. Current non-invasive imaging strategies using reporter
gene expression have been applied to analyze adenoviral vectors. The major drawback to approaches that tag viruses with
reporter genes is that these systems require initial viral infection and subsequent cellular expression of a reporter gene to
allow non-invasive imaging. As an alternative to conventional vector detection techniques, we developed a specific genetic
labeling system whereby an adenoviral vector incorporates a fusion between capsid protein IX and human metallothionein.
Our study herein clearly demonstrates our ability to rescue viable adenoviral particles that display functional
metallothionein (MT) as a component of their capsid surface. We demonstrate the feasibility of 99mTc binding in vitro to
the pIX-MT fusion on the capsid of adenovirus virions using a simple transchelation reaction. SPECT imaging of a mouse
after administration of a 99mTc-radiolabeled virus showed clear localization of radioactivity to the liver. This result strongly
supports imaging using pIX-MT, visualizing the normal biodistribution of Ad primarily to the liver upon injection into mice.
The ability we have developed to view real-time biodistribution in their physiological milieu represents a significant tool to
study adenovirus biology in vivo.
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Introduction
Barrier to gene therapy approaches for cancer
As the limits of existing treatments for cancer are recognized,
clearly novel therapies must be considered for successful
treatment; cancer therapy using adenovirus (Ad) vectors is a
promising strategy. The existing approaches to gene therapy/
virotherapy of cancer can be divided into five broad categories:
a) mutation compensation, b) molecular chemotherapy,
c) genetic immunopotentiation, d) genetic modulation of
resistance/sensitivity, and e) oncolytic therapy or virotherapy.
Through 2009, Ad vectors were employed in a quarter of gene
therapy clinical trials worldwide [1]. However tracking the
biodistribution of Ad vectors in vivo is limited to invasive
procedures such as biopsies, which are error prone, non-
quantitative, and do not give a full representation of the
pharmacokinetics involved.
Current detection methods are inadequate for Ad vector
systems
Several imaging studies have attempted to address this problem,
including the use of positron emission tomography (PET) scanning
to detect herpes simplex virus thymidine kinase (HSV-TK) as a
reporter of oncolytic herpes simplex virus replication [2].
However, detection was restricted to infected cells expressing the
reporter gene, which does not represent the physical distribution of
the virus itself. Another group employed soluble hCEA and bhCG
peptide markers as a way to monitor oncolytic measles virus
therapy in mice, which correlated with therapeutic outcome but
could not show viral localization [3]. Other conventional imaging
systems for adenovirus based gene therapy have been designed to
detect transgene expression of reporters such as green fluorescent
protein (GFP) [4], somatostatin receptor type 2 (SSTR-2) [5,6],
sodium iodide symporter [7], luciferase [8], and HSV-TK [9].
Despite their utility for assessing gene delivery and expression,
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these reporters by themselves are not suitable for monitoring
physical biodistribution. The major drawback to approaches that
tag viruses with reporter genes is that these systems require initial
viral infection and subsequent cellular expression of a reporter
gene to allow non-invasive imaging.
Capsid protein IX is a potential location for labeling Ads
To overcome this limitation, we devised a novel approach to
incorporate the humanmetallothionein (MT) protein as a fusion to the
Ad minor capsid protein pIX (pIX). This would allow us to directly
label Ads and determine if this approach can be used to monitor virus
delivery in vivo by non-invasive imaging. Recent work by several
groups has defined the C-terminus of pIX as a locus presenting
incorporated ligands on the virus surface. Protein IX is a small
polypeptide of 140 residues (14.7 kDa) that acts as a cement protein to
stabilize hexon-hexon interaction and therefore the capsid structure
itself [10]. Four trimers of pIX interact with a group of nine (GON)
hexons in each facet of the icosahedron [11], resulting in 240 copies of
the protein per virion [12]. In addition, pIX has been implicated as a
transcriptional activator of several viral and cellular TATA-containing
promoters, including adenoviral E1A, E4, and major late promoters
[13]. Based on the understanding the pIX C-terminus is surface
exposed [14,15], pIX has been exploited as a location to incorporate
heterologous peptides (namely lysine octapeptide and polylysine) into
its C-terminus for retargeting purposes [16]. A single chain variable
fragment (scFv) against beta-galactosidase [17] and a single-chain T-
cell receptor (scTCR) directed against the melanoma-associated
antigen (MAGE) [18] were also successfully fused to pIX and
assembled into virions. Based on these data, we also demonstrated that
pIX would be a suitable location for incorporating reporter genes,
such as firefly luciferase [19] and GFP [20,21]. However, these fusions
require optical imaging techniques that are not clinically compatible
and may be limited by depth of light penetration.
Non-invasive imaging using a pIX-MT fusion
MT is a ubiquitous, low molecular weight, metal-binding protein
that participates in heavy metal metabolism and detoxification.
Mammalian forms of MT bind seven metal ions in tetrahedral
metal-thiolate clusters, including a commonly used medical isotope
of technetium (99mTc) useful for radioimaging by single photon
emission computed tomography (SPECT) [22]. Several studies have
shown that MT can be genetically engineered or conjugated with
targeting proteins such as monoclonal antibodies [23,24,25] and
streptavidin [26], and that 99mTc can be bound in vitro to the
complexes using a simple transchelation reaction.
In our current study, we sought to incorporate MT within pIX to
determine if a fusion of this type could retain functionality in this
context. Our study herein clearly demonstrates our ability to rescue
viable adenoviral particles that display functional MT as a
component of their capsid surface. The alternative display of MT
on the capsid may offer advantages with respect to direct functional
applications of this gene product. Our innovative use of a structural
fusion protein incorporating MT provides the non-invasive imaging
advantages for detecting physical biodistribution and spread of Ad
vectors after administration that is not possible employing a reporter
gene. Further, the ability to noninvasively observe Ad function on a
whole-body level, allows the possibility of detecting virus dissem-
ination outside the tumor site(s) for monitoring clinical safety.
Materials and Methods
Cell culture
Human embryonic kidney epithelial (HEK293) cells were
obtained from and cultured in the medium recommended by
the American Type Culture Collection (Manassas, VA). The
HEK293 cell line was grown in high glucose Dulbecco’s Modified
Eagle Medium (DMEM; Invitrogen; Carlsbad, CA) supplemented
with 10% fetal bovine serum (Atlanta Biologicals; Lawrenceville,
GA), 100 IU/ml penicillin, 100 mg/ml streptomycin, and 2 mM
L-glutamine. The cells were incubated at 37uC and 5% CO2
under humidified conditions.
Animals
Female C57BL6 mice at 4–6 weeks of age were obtained from
Charles River Laboratories (Wilmington, MA). All animals
received humane care based on guidelines set by the American
Veterinary Association. The experimental protocols involving live
animals were reviewed and approved by the Institutional Animal
Care and Use Committee of LSU Health Sciences Center at
Shreveport (Protocol #P-08-017). For the SPECT imaging
studies, mice were also pretreated with warfarin (5 mg/kg)
dissolved in peanut oil and administered by subcutaneous injection
at 3 days and 1 day prior to the Ad vector injections.
Recombinant Adenovirus Construction
A pIX-MT intermediate sequence in pUC57 was constructed by
synthesizing a 932 bp DNA fragment (GenScript; Piscataway, NJ)
corresponding to: amino acids 106–140 of the Ad serotype 5 (Ad5)
pIX protein coding sequence, followed by a 15 amino acid linker
(GGGGSGGGGSGGGGS), amino acids 1–61 of the human
metallothionein 1A sequence, a 16 bp DNA linker sequence
(TGAGCTAGCGACGTCA), and the 583 bp DNA sequence
immediately upstream of the pIX gene (bp 4032–4614; Genbank
accession AY339865). This synthetic DNA fragment was subcloned
directly into the MfeI - BstXI sites of the AdenoVatorCMV5 shuttle
vector (QBiogene; Carlsbad, CA). A turboGFP cDNA sequence
(Axxora; San Diego, CA) was also subcloned into the CMV5
expression polylinker site of pAdenoVatorCMV5 for use as a
reporter gene. The resulting pAdenoVatorCMV5-tGFP-pIX-MT
shuttle vector was used to construct an adenovirus by homologous
recombination with pAdEasy1 (containing the E1 and E3 deleted
Ad5 backbone) in E. coli using methods previously described [27].
The resultant recombinant plasmid was linearized with Pac I and
transfected into HEK293 cells to generate the Ad-tGFP-pIX-MT
virus. Construction of the Ad-IX-EGFP and Ad-CMV-EGFP
vectors used as controls has been described previously [20].
Virus propagation and purification
Viruses were propagated in HEK293 cells, which do not express
wild-type pIX. Viruses were purified by double CsCl ultracentri-
fugation and dialyzed against Dulbecco’s phosphate buffered
saline containing 10% glycerol. Final aliquots of virus were
analyzed for viral particle (v.p.) titer using absorbance at 260 nm
and a conversion factor of 1.161012 viral particles per absorbance
unit (v.p./OD260). Multiplicity of infection (m.o.i.) was deter-
mined using an Adeno-X Rapid Titer Kit (Clontech; Mountain
View, CA) and represents the number of infectious units (i.f.u.) of
virus. Viruses were stored at 280uC until use. The Ad-tGFP-pIX-
MT virus titer used was 1.261011 v.p./mL and 1.46109 i.f.u./mL.
Fluorescence Microscopy
Epifluorescence microscopy was performed using an inverted
Eclipse TE300 microscope (Nikon Instruments, Melville, NY)
equipped with a CoolSNAP fx monochrome CCD camera (Roper
Scientific - Princeton Instruments; Trenton, NJ). Images were
acquired with a 20X objective and processed with IPLab imaging
software (Scanalytics, Inc.; Fairfax, VA).
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Western Blot Analysis
Purified Ad-tGFP-pIX-MT and Ad-CMV-EGFP virions were
resolved on precast 4–20% gradient SDS-PAGE gels (Thermo
Scientific Pierce; Rockford, IL), and transferred to nitrocellulose
membranes. Staining was performed using 1:500 dilution of an
anti-human metallothionein monoclonal antibody (clone
UC1MT; Abcam, Inc.; Cambridge, MA) or 1:500 dilution of a
monoclonal anti-adenovirus fiber monoclonal antibody (clone
4D2; Abcam), followed by a 1:1,000 dilution of a secondary HRP-
conjugated goat anti-mouse IgG antibody (Santa Cruz Biotech-
nology, Inc.; Santa Cruz, CA). Specific protein bands were
detected by chemiluminescence using Amersham ECL Plus
reagents (GE Healthcare; Piscataway, NJ).
Assessment of Replication of Virus
Increase in the copy number of the E4 gene was used as a
surrogate to determine virus propagation. At 1, 2, 3, and 4 days
post-infection of HEK293 cells, aliquots of culture media (300 mL)
were removed and frozen at 280uC until use. Total DNA was
purified using a QIAamp DNA Mini Kit (Qiagen, Valencia, CA).
E4 gene copy number was determined using specific E4 primers
and TaqMan probes for real-time polymerase chain reaction
(PCR) as previously described [28] with TaqMan fast reagents
(Applied Biosystems, Framingham, MA) and measured against a
standard curve made from known amounts of adenovirus genome.
Thermostability assay
Fifty thousand HEK293 cells were subcultured overnight into
24-well tissue culture plates with 1 ml DMEM medium containing
10% FBS. Prior to infection, the viruses were incubated for 0, 15,
45, 60, and 90 min time periods at 45uC, and subsequently, the
heat-treated viruses were used to infect the HEK293 cells. At 24 h
post infection, the plates were analyzed for relative fluorescence
intensity of GFP using a Fluoroskan Ascent Microplate Fluorom-
eter (Thermo Fisher Scientific; Waltham, MA).
Radiolabeling of virus and gel chromatography
For radiolabeling Ad virions, 99mTc-pertechnetate was reduced
in the presence of glucoheptonate using a commercially available
kit (DRAXIS Specialty Pharmaceuticals Inc.; Kirkland, Quebec,
Canada) for 15 min at room temperature and added directly to
aliquots of Ad at a ratio of 10:1. Incubation with Ads proceeded
for 60 min at 37uC. Purification of free 99mTc from labeled
adenovirus virions was performed by gel filtration using Sephacryl
S-200 HR (GE Healthcare; Piscataway, NJ). Sephacryl resin was
loaded into a 20 mL disposable column (Bio-Rad) and pre
equilibrated with phosphate buffered saline (PBS) containing 5%
glycerol. One mL aliquots of radiolabeled virus were applied to the
columns, and 10 drop fractions were collected using an automated
fraction collector. The viral particle (v.p.) titer of each fraction was
determined by measuring the absorbance at 260 nm in a
spectrophotometer, using a conversion factor of 1.161012 v.p./
OD260 [29]. The radioactivity was measured with a dose
calibrator (Capintec, Inc.; Ramsey, NJ).
Metal competition assay
Aliquots of the radiolabeled Ad-tGFP-pIX-MT were incubated in
the absence or presence of non-radioactive competitor metal ions. After
addition of competitor metals using 100X stock solutions, the aliquots
were incubated at room temperature for 15 min. The adenovirus-
bound and free 99mTc were separated by gel chromatography using
micro spin columns (Bio-Rad; Hercules, CA), and quantified using a
NaI (Tl) c-counter (PerkinElmer Inc.; Waltham, MA).
HPLC analysis of 99mTc radiolabel stability
Aliquots of the radiolabeled Ad-tGFP-pIX-MT were incubated
for 30 min at 27uC in PBS containing 5% glycerol, with the
absence presence of 50% mouse serum (Sigma-Aldrich; St. Louis,
MO). Aliquot were also incubated for 30 min with 50% mouse
serum at increasing temperatures (37, 42, 45, 50, and 55uC).
Afterwards, adenovirus particles were analyzed by HPLC as
previously described [30] on a Dionex DX500 Chromatography
System (Dionex Corp; Sunnyvale, CA) using a strong anion
exchange Bio-Monolith QA HPLC column (Agilent technologies;
Santa Clara, CA). The HPLC system was equipped with in-line
UV (260 nM) and Nal(Tl) gamma scintillation detectors interfaced
to a multichannel analyzer. Software analysis was performed for
the UV detector using Chromeleon 6.80 (Dionex) and was
performed for the gamma scintillation detector using PeakSimple
3.85 (SRI Instruments, Torrance, CA).
SPECT/CT scanning of Ad-infected mice
Two mice were injected via the tail vein with approximately
1 mCi of the radiolabeled Ad-tGFP-pIX-MT, and image acquisi-
tion was started at 60 min afterwards. Similarly, one mouse was
injected with approximately 1 mCi of 99mTc-glucoheptonate and
one mouse was injected with approximately 1 mCi of 99mTc-
pertechnetate. The animals were anesthetized using isoflurane and
fixed in a prone position on the bed and center of rotation relative to
the gantry of a dedicated small animal trimodality PET/SPECT/
CT system (Gamma Medica-Ideas, Northridge, CA). After 60 min,
3D SPECT imaging was performed in a step-and-shoot manner
using the following acquisition parameters: 64 projections, 30
seconds/projection (35-minute image acquisition), with a 140 keV
photopeak 610% window. SPECT 3D reconstruction was carried
out using Amira software (Gamma Medica-Ideas). Immediately
after SPECT imaging was performed, CT images were acquired
using the same coordinates as SPECT with 256 projections and
102461024 projection matrix size and a voltage of 60 kV;
reconstructions were performed using filtered back-projections.
Reconstructed data was saved as DICOM files and were imported
for further analysis to AMIDE (version 0.9.2; Andy Loening)
freeware. Volumes of interest (VOIs) from each image were
manually defined and image analyses were performed; the AMIDE
ROI statistics tool was used to obtain the mean voxel values for the
VOI. The percent activity for each VOI was determined as (VOI
mean voxel value6VOI voxel number)/(total image mean voxel
value6total image voxel number)610.
Statistical analysis
All data are expressed as means 6 SE. In vitro experiments were
performed in triplicate. Statistical analysis was carried out using
Student’s t-test, or for multiple comparisons, two-way ANOVA
using GraphPad Prism version 5.0 software. Statistical significance
was set at P,0.05.
Results
Constructing an adenovirus vector containing a pIX-MT
fusion
We initiated this work to construct an adenovirus by using an E.
coli recombination system with a shuttle vector and the adenovirus
backbone plasmid. As a labeling system, we incorporated the MT
coding sequence as a C-terminus fusion to the pIX protein. We
used the E. coli recombination system to generate a recombinant
replication deficient Ad containing an E1A expression cassette
with tGFP sequence under control of the CMV promoter. The
resulting recombination inserted shuttle vector sequences contain-
pIX-Metallothionein Incorporation into Adenovirus
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ing the expression cassette and pIX-MT fusion gene into the
pAdEasy1 adenovirus backbone replacing the E1A and E1B
sequences. (Fig. 1A). The identity of the recombinant genome was
validated by restriction enzyme digestion and PCR analysis and was
confirmed by DNA sequencing (data not shown). The resulting
pAd5.CMV5-tGFP-pIX-MT plasmid vector was used to rescue an Ad
virion by linearization with Pac I and transfection into HEK293 cells.
After transfection, positive Ad plaques were detected by fluorescence
microscopy (Fig. 1B). Propagated Ad-tGFP-pIX-MT virus was purified
by double CsCl ultracentrifugation. After virus purification, a
recombinant pIX-MT fusion protein was clearly detected as a 21 kD
band by western blot analysis of the purified virus using an anti-
metallothionein antibody (Fig. 1C). This band corresponds to the
expected molecular weight of the pIX-MT, and was absent in purified
Ad-CMV-EGFP virus. As a control, both the Ad-tGFP-pIX-MT and
the Ad-CMV-EGFP virus showed 60 kD bands by western blot
analysis using an anti-Ad fiber protein. These results indicate that
correct introduction of the MT protein into the viral capsid of an
adenovirus by fusing it with the minor capsid protein IX allows the
rescue of an infectious virion.
Analysis of viral DNA replication
To determine DNA replication properties of Ad-tGFP-pIX-
MT, the following experiment was performed. Ad E4 copy
numbers were analyzed after cells were infected with virus. In
brief, 10 i.f.u./cell of Ad-tGFP-pIX-MT, Ad-CMV-EGFP, or Ad-
IX-EGFP was used to infect the Human embryonic kidney
epithelial (HEK293) cell line. Aliquots of medium were collected
on 1, 2, 3, and 4 days post-infection. Total DNA was extracted
from the medium (which was used to incubate infected cells) and
analyzed for Ad5 viral E4 DNA copy number (Fig, 2). Medium
from uninfected cells was also obtained at each time point to serve
as a base line for viral replication. At 1 day post-infection, the E4
copy number for Ad tGFP-pIX-MT and Ad-IX-EGFP were
observed to be approximately 52.6 and 7.5 copies per 100 mL
aliquot of medium, while the E4 copy number value for Ad-CMV-
EGFP was 12. By 4 days post-infection, Ad5 E4 copy number for
each of the adenoviral constructs was dramatically increased to
approximately 41,200, 75,900, and 81,700 copies per 100 mL
aliquots of media for Ad-tGFP-pIX-MT, Ad-IX-EGFP, and Ad-
CMV-EGFP, respectively. Taken together, these data indicate
that the adenovirus constructs with modified pIX genes (tGFP-
pIX-MT and Ad-IX-EGFP) showed similar replication patterns in
293 cells, and this replication is comparable to an adenovirus
construct with a wild-type pIX gene (Ad-CMV-EGFP).
Thermostability of Ad-tGFP-pIX-MT virions
Modification of pIX may destabilize the capsid structure; this
possibility was assessed by comparing the thermostability of Ad-
tGFP-pIX-MT to a control Ad-CMV-EGFP virus containing the
wild-type pIX and to an Ad-IX-EGFP virus incorporating the
enhanced GFP (EGFP) protein as a fusion to pIX. Virus samples
were incubated at 45uC for various times and then quantified in
terms of infectious titer (Fig. 3). Beginning at 15 min of incubation,
the infectious titer of all viruses decreased in an exponential
fashion; the infectious titer for Ad-CMV-EGFP and Ad-tGFP-
pIX-MT were 70.8% and 40.4% of initial titers, respectively,
while the infectious titer for Ad-IX-EGFP was only 4.8% if the
initial titer. Viral titers continued to decrease between 15 and
90 min of incubation, with the time for 50% remaining titer of Ad-
Figure 1. Construction and analysis of a pIX-MT containing adenovirus. (A) Schematic representation of pIX-MT and a CMV-tGFP expression
cassette inserted into the Ad5 genome. (B) Expression of GFP in cells infected with Ad-tGFP-pIX-MT shows formation of an individual plaque. (C)
Detection of adenovirus fiber and metallothionein proteins incorporated into the purified Ad-tGFP-pIX-MT and Ad-CMV-EGFP viral particles by
western blot analysis.
doi:10.1371/journal.pone.0016792.g001
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CMV-EGFP at 26.7 min, Ad-tGFP-pIX-MT at 11.9 min, and
Ad-IX-EGFP at 3.2 min. These results indicate that the MT
addition to pIX did negatively affect the thermostability of Ad-
tGFP-pIX-MT following exposure of the virus to high tempera-
ture compared to a virus containing wild-type pIX. However,
when comparing the thermostability curves, this effect was
significantly less than that of incorporating a pIX-EGFP fusion
(two-way ANOVA, P,0.001).
Radiolabeling of Ad-tGFP-pIX-MT with 99mTc
We tested whether Ad-tGFP-pIX-MT could be radiolabeled by
99mTc binding in vitro. In this representative experiment, 99mTc-
pertechnetate was reduced in the presence of glucoheptonate for
15 min at room temperature and added directly to the adenovirus
solution. Incubation with Ad proceeded for 60 min at 37uC.
Purification of free 99mTc from labeled adenovirus virions was
performed by gel filtration using a Sephacryl S-200 column. As shown
in Fig. 4, the specific activity of the peak at fraction 30 corresponding to
the highest adenovirus infectious activity was approximately
0.13 mBq/v.p. for the Ad-tGFP-pIX-MT. Importantly, an adenovirus
construct Ad-CMV-EGFP containing the wild-type pIX showed lower
specific activity at fraction 30 (0.006 mBq/v.p.), possibly from non-
specific 99mTc binding to free sulfhydryl groups [31] on the Ad capsid
surface. These results demonstrate the feasibility of 99mTc binding in
vitro to the pIX-MT fusion on the capsid of adenovirus virions using a
simple transchelation reaction.
Metal competition assay
The heavy metals that can be bound by MT include Ag, Au, Bi,
Cd, Co, Cu, Fe, Hg, Ni, Pb, Sn, Tc, and Zn, [32], as well as Re
[33]. To determine the specificity of 99mTc binding, we performed
a metal competition assay using increasing concentrations of
CdCl2, CoCl2, CuCl2, or ZnCl2. As shown in Fig. 5, the bound
radioactivity was competed with increasing concentrations of
metal, with half maximal concentrations required for displacement
of 99mTc. Importantly, these results correlate with the relative
order of in vitro binding affinities to MT determined to be Cu. Cd
. Zn . Co [34]. In addition, Cu was capable of displacing 99mTc
from the radiolabeled Ad-tGFP-pIX-MT between 0.1 and 1 mM.
However, this concentration of Cu required for displacement is
much higher than physiological levels of Cu determined in serum
of normal mice, at approximately 400 ng/mL (0.006 mM) [35].
Stability of 99mTc radiolabel on the Ad-tGFP-pIX-MT
virions
Serum stability of the radiolabel on Ad-tGFP-pIX-MT was
investigated by incubating virions for 30 min in 50% normal mouse
serum (Fig. 6). In the absence of serum, we could detect no loss of
radioactivity at room temperature, 27uC or 37uC after incubation
for 30 min (data no shown). However, compared with radiolabeled
virus incubated in the absence of serum, approximately 80% of the
radioactivity was still bound in 50% serum after incubation at 27,
Figure 2. Replication of Ad-tGFP-pIX-MT compared to Ad-CMV-
EGFP and Ad-IX-EGFP. Viral copy number was used as an indicator of
viral replication in HEK293 cells. Growth medium was collected at 1, 2, 3,
and 4 days after infection with Ad-tGFP-pIX-MT, Ad-CMV-EGFP, or Ad-
IX-EGFP at an m.o.i. of 10 i.f.u/cell. Each point represents the mean6 SE
of three replicate samples.
doi:10.1371/journal.pone.0016792.g002
Figure 3. Thermostability of Ad-tGFP-pIX-MT compared to Ad-
CMV-EGFP and Ad-IX-EGFP. The thermostability of each virus was
determined by incubation at 45uC for various times and quantified in
terms of infectious titer. Each point represents the mean 6 SE of three
replicate samples.
doi:10.1371/journal.pone.0016792.g003
Figure 4. Gel filtration column profile of 99mTc binding to
adenovirus containing a pIX-MT fusion protein. After incubation
with 99mTc glucoheptonate, the Ad-tGFP-pIX-MT virus containing a pIX-
MT fusion protein and the Ad-CMV-EGFP virus containing a wild-type
pIX protein were purified by gravity gel filtration using 20 mL Sephacryl
S-200 columns. Each point represents the specific activity in mBq/v.p of
individual 10 drop fractions collected.
doi:10.1371/journal.pone.0016792.g004
pIX-Metallothionein Incorporation into Adenovirus
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37, and 42uC. This loss of approximately 20% radioactivity at these
temperatures may represent loss from low affinity binding sites to
99mTc. When the virus was incubated at higher temperatures, the
remaining bound radioactivity was decreased to 46% radioactivity
at 45uC, 40% radioactivity at 50uC, and 19% radioactivity at 55uC.
This result is similar to the results in Fig. 3 showing inactivation of
virus infectivity at 45uC, as well as previous data demonstrating
virus inactivation at temperatures between 48 and 54uC [36].
SPECT analysis of adenovirus administration in vivo
After radiolabeling the Ad-tGFP-pIX-MT, we determined
whether SPECT imaging could be used to monitor Ad
biodistribution and uptake in vivo. In the experiment shown in
Fig. 7, a female C57BL6 mouse was injected intravenously with
99mTc-labeled Ad-tGFP-pIX-MT. One hour after administration,
the animal was imaged; clear localization of activity to the liver
(4568%) was seen (Fig. 7C), and bladder activity (3263%) was also
detected. This result strongly supports imaging using pIX-MT,
visualizing the normal biodistribution of Ad primarily to the liver
upon injection into mice. As a control, in vivo imaging of a mouse
in Fig. 7A injected with 99mTc-pertechnetate alone showed no liver
signal, with localization to stomach (1463%) and bladder
(1662%). Likewise, in vivo imaging of a control mouse in Fig. 7B
injected with 99mTc-glucoheptonate alone also showed no liver
activity, with activity localization to kidneys (2268%).
Liver tropism of administered Ad5 vectors results in rapid
sequestration. Key components of this process have recently been
elucidated, involving Ad capsid interaction with multiple vitamin
K-dependent coagulation factors [37]. Specifically, coagulation
factor6 (FX) binds to the capsid hexon protein and mediates the
majority of the Ad5 liver tropism, presumably via heparin sulfate
proteoglycan-mediated pathways [38,39,40]. Pretreatment with
the drug warfarin, which inhibits vitamin K-dependent coagula-
tion factor production, can deplete circulating FX levels and
decrease the liver tropism of i.v. administered Ad5. As shown in
Fig.7D, warfarin pretreated mice exhibited a decrease in liver
activity (1468%) compared with untreated mice (Fig. 7C), as well
as a diffuse peritoneal imaging pattern. Together, these data
illustrate that the pIX-MT fusion retains its metal binding capacity
at the pIX locale and can function in an in vivo context, thus
making non-invasive imaging analysis feasible.
Discussion
We have shown herein that our novel pIX-MT labeling strategy for
adenovirus yields rescuable virions. The pIX protein is a structural
component of the Ad that stabilizes hexon-hexon interactions; there
are 240 pIX molecules per virion. With a capacity of 7 metal ions
bound per pIX-MT fusion protein, as many as 1680 metal ions can
bind per virion. The highly conserved metallothionein structure
potentially offers the additional advantage of lower immunogenicity, by
‘‘shielding’’ the Ad from preexisting humoral immunity [41]. Direct
western blot analysis of purified Ad-tGFP-pIX-MT produced a protein
band that corresponded to a pIX-MT fusion. This data indicates that
the pIX-MT fusion was successfully incorporated into the Ad pIX
locale. Most importantly, Ad-tGFP-pIX-MT demonstrated specific
99mTc binding in vitro when incubated with 99mTc-glucoheptonate.
This study also demonstrated our ability to create a virus that
encompasses a protein motif useful for SPECT imaging. The majority
of previous imaging strategies have focused on incorporating reporter
gene using a single imaging modality whereas; our unique virus
incorporates the potential for multiple imaging modalities.
Knowledge of biodistribution is crucial in assessing the efficacy
of Ad mediated therapies. Clinical trials completed so far have had
to rely on conventional histology of biopsy specimens and analysis
of body fluids to detect virus; the majority of biodistribution studies
have involved PCR-based techniques. For example, after intrave-
nous administration at the highest dose of a replication deficient
Ad5CMV-p53, the presence of a unique 89 bp amplicon specific
to Ad5CMV-p53 DNA was detectable by Q-PCR in the plasma of
4 of 5 patients at day 14 and 2 of 3 assessable patients at day 28
[42]. In addition, the presence of Ad5CMV-p53 DNA was
detected within biopsies of tumor metastasis distant from the
intravenous administration site in 6 of 7 assessable patients.
However, these results only provide data on the presence of a
nucleotide sequence and not on the presence of viral vector
Figure 5. Concentration dependence of competition for metal
binding to purified virus. Aliquots of 99mTc-radiolabeled Ad-tGFP-
pIX-MT were incubated for 15 min at 37uC with the indicated
concentrations of CdCl2, CoCl2, CuCl2, or ZnCl2. Virus bound
99mTc
was determined counting radioactivity after purification through micro
spin columns.
doi:10.1371/journal.pone.0016792.g005
Figure 6. Comparison of 99mTc radiolabel stability on Ad-tGFP-
pIX-MT. After 30 min incubation with 50% normal mouse serum at
increasing temperatures, samples were analyzed by HPLC on a Bio-
Monolith column for 99mTc-radiolabeled Ad-tGFP-pIX-MT in each
sample. Radioactivity of peaks corresponding to Ad-tGFP-pIX-MT were
quantified and normalized to the radio activity of peaks corresponding
to Ad-tGFP-pIX-MT after 30 min in the absence of serum at 27uC. Each
point represents the mean 6 SE of three replicate samples.
doi:10.1371/journal.pone.0016792.g006
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particles. In addition, these results highlight the shortcomings of
current vector detection methods: the need to acquire multiple
biopsies using an invasive procedure that is prone to sampling
error and is concomitantly impractical for repeated monitoring of
the entire tumor.
Radiotracer imaging technologies that can measure the distribution
of radiolabeled tracers in vivo are now widely available and have a wide
range of research and clinical applications. Two classes of radiotracer
imaging systems exist: those designed to imaging SPECT radionuclides
such as 99mTc and those designed to image PET radionuclides such as
64Cu. Thus, besides SPECT imaging using 99mTc, the pIX-MT
could also be used for non-invasive PET imaging, using 64Cu
binding. SPECT and PET techniques are able to image as low as
10-10 to 10-12 M of radiolabeled moieties. Each imaging modality has
advantages and disadvantages, and thus has specific applications. In
general, PET has higher spatial resolution and sensitivity, and is easier
to quantify than SPECT. However, SPECT radiotracers are cheaper
and much more widely available. Likewise, next-generation SPECT
systems have dramatically increased sensitivity. In addition to
evaluation of biodistribution by initially in vitro 99mTc radiolabeled
replication deficient Ads, we expect virions containing the pIX-
metallothionein fusion proteins can also be potentially labeled using
188Re [33]. This method could offer the advantage of dual-functional
SPECT imaging and radionuclide therapy [43,44,45].
In total, as hypothesized these data clearly establish the functionality
of pIX-MT when incorporated into the adenovirus capsid at the pIX
locale. The ability to view real-time molecular biodistribution events in
their physiological milieu represents a significant tool to study
adenovirus biology in vivo. Although in vitro studies can serve as a
simplified controlled model to study Ad behavior in tumor cells, their
simplicity strips them of the complexities of a three-dimensional tumor
environment that has profound effects on Ad performance. Ultimately,
the highest yield of valuable information about Ads will come from in
vivo preclinical studies and application of Ad vectors in patients.
It has become clear that cell-specific transductional retargeting
of Ad vectors is of fundamental importance with respect to
deriving their full benefit in the context of the gene therapies
[46,47,48]. These transductional retargeting strategies, whereby
Ad viruses are designed to selectively infect target cells, have the
potential for reducing deleterious side effects and increasing the
therapeutic index of these agents. The pIX-MT labeling system
demonstrated herein, offers the potential for noninvasive dynamic
imaging of Ad biodistribution that can be easily used by existing
nuclear medicine imaging modalities. Importantly, this tool can be
used for preclinical development of transductional retargeted Ads,
and it would be practical in the clinical setting to monitor the
therapeutic application of these agents.
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Figure 7. SPECT imaging analysis of a mouse injected with an adenovirus containing a capsid-incorporated pIX-MT fusion protein.
C57BL6 mice were injected intravenously with approximately 1 mCi of 99mTc in 0.3 mL PBS, and scanned at 30 min after the injection. Afterwards, 3D
renderings of SPECT images in blue-purple-red-yellow scale against CT projections in grey scale were obtained. Shown are: (A) coronal image of a
normal mouse injected with 99mTc-pertechnetate; (B) coronal image of a mouse injected with 99mTc-glucoheptonate; (C) coronal and sagittal images
of a normal mouse injected with 99mTc-Ad-tGFP-pIX-MT; and (D) coronal and sagittal images of a mouse pretreated with warfarin injected with 99mTc-
Ad-tGFP-pIX-MT.
doi:10.1371/journal.pone.0016792.g007
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